384
Views
13
CrossRef citations to date
0
Altmetric
Research Article

Clinicopathologic implication of A20/TNFAIP3 deletion in diffuse large B-cell lymphoma: an analysis according to immunohistochemical subgroups and rituximab treatment

, , , , , & show all
Pages 1934-1941 | Received 16 Aug 2012, Accepted 20 Dec 2012, Published online: 16 Feb 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Soo Jeong Nam, Heounjeong Go, Jin Ho Paik, Tae Min Kim, Dae Seog Heo, Chul Woo Kim & Yoon Kyung Jeon. (2014) An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leukemia & Lymphoma 55:11, pages 2466-2476.
Read now

Articles from other publishers (12)

Fengbo Huang, Yachao Ruan, Xiaojuan He, Hui Lian & Jinhua Yang. (2023) Clinicopathologic and mutational profiles of primary breast diffuse large B cell lymphoma in a male patient: case report and literature review. World Journal of Surgical Oncology 21:1.
Crossref
Cunte Chen, Lingling Zhou, Lihua Zhu, Gengxin Luo, Liang Wang, Chengwu Zeng, Hongsheng Zhou & Yangqiu Li. (2022) TNFAIP3 mutation is an independent poor overall survival factor for patients with T‐cell acute lymphoblastic leukemia . Cancer Medicine 12:4, pages 3952-3961.
Crossref
Yasuko Kuribayashi-Hamada, Mariko Ishibashi, Atsushi Tatsuguchi, Toshio Asayama, Namiko Takada-Okuyama, Asaka Onodera-Kondo, Keiichi Moriya, Takehito Igarashi, Hiroyuki Onose, Sakae Tanosaki, Norio Yokose, Hiroki Yamaguchi & Hideto Tamura. (2022) Clinicopathologic Characteristics and <i>A20</i> Mutation in Primary Thyroid Lymphoma. Journal of Nippon Medical School 89:3, pages 301-308.
Crossref
Cunte Chen, Zheng Chen, Ling Huang, Lingling Zhou, Lihua Zhu, Sichu Liu, Gengxin Luo, Wenyu Li, Chengwu Zeng & Yangqiu Li. (2021) TNFAIP3 mutation may be associated with favorable overall survival for patients with T-cell lymphoma. Cancer Cell International 21:1.
Crossref
Hyun Jung Kwon, Jeong Mi Yang, Jeong-Ok Lee, Jong Seok Lee & Jin Ho Paik. (2018) Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma. Journal of Translational Medicine 16:1.
Crossref
Jeong Mi Yang, Ji-Young Jang, Yoon Kyung Jeon & Jin Ho Paik. (2018) Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma. Journal of Translational Medicine 16:1.
Crossref
Hyein Ahn, Jeong Mi Yang, Yoon Kyung Jeon & Jin Ho Paik. (2018) Clinicopathologic implications of TNFAIP3/A20 deletions in extranodal NK/T-cell lymphoma. Genes, Chromosomes and Cancer 57:5, pages 231-239.
Crossref
Gaurav Goyal, Austin Huy Nguyen, Kayla Kendric & Gabriel C. Caponetti. (2016) Composite lymphoma with diffuse large B-cell lymphoma and classical Hodgkin lymphoma components: A case report and review of the literature. Pathology - Research and Practice 212:12, pages 1179-1190.
Crossref
Zixing Liu, Kelly R. Smith, Hung T. Khong, Jingshan Huang, Eun-Young Erin Ahn, Ming Zhou & Ming Tan. (2016) miR-125b regulates differentiation and metabolic reprogramming of T cell acute lymphoblastic leukemia by directly targeting A20. Oncotarget 7:48, pages 78667-78679.
Crossref
Wenxiu Yang, Yi Li, Pinhao Li & Lingling Wang. (2016) PMA/IONO affects diffuse large B-cell lymphoma cell growth through upregulation of A20 expression. Oncology Reports.
Crossref
Hong Cen, Xiaohong Tan & Baoping Guo. (2015) A20 Mutation Is Not a Prognostic Marker for Activated B-Cell-Like Diffuse Large B-Cell Lymphoma. PLOS ONE 10:12, pages e0145037.
Crossref
Jin Ho Paik, Soo Jeong Nam, Tae Min Kim, Dae Seog Heo, Chul-Woo Kim & Yoon Kyung Jeon. (2014) Overexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas. BMC Cancer 14:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.